Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS014 and Toripalimab with TACE in unresectable HCC
NCT06882876Phase 1Enrolling by invitation
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Nanobodies (VHH), Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of exenokine-21 in hepatocellular carcinoma (HCC), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Rate of adverse events at 2 years. Started Jul 2025; status: enrolling by invitation.
02
Drugs
exenokine-21
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06882876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06882876.